Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.88 |
| ▸ | NPC1 | O15118 | 12/20 | 0.88 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30944411 | 1.00 | RAB9A (0.88) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL30944422 | 1.00 | RAB9A (0.88) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL30944350 | 1.00 | RAB9A (0.88) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL28522078 | 1.00 | RAB9A (0.88) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL28529297 | 1.00 | RAB9A (0.88) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL24071576 | 0.89 | RAB9A (0.85) | RAB9ANPC1CHKAMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL31419712 | 0.86 | RAB9A (0.69) | RAB9ANPC1CHKAMAPTMAOA | |
| SCHEMBL24071463 | 0.86 | NPC1 (0.73) | RAB9ANPC1CHKAMAPTALDH1A1 | |
| SCHEMBL24071516 | 0.86 | RAB9A (0.72) | RAB9ANPC1CHKAMAPTALDH1A1 | |
| SCHEMBL31419754 | 0.86 | RAB9A (0.72) | RAB9ANPC1CHKAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655225-B2 | Antimycobacterial heterocyclic amides | CRESTONE, INC. (US) | 2023-05-23 | — | — | US | claimed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | claimed |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | CRESTONE, INC. | 2021-01-07 | — | — | US | claimed |
| EP-3758697-B1 | NOVEL ANTIMYCOBACTERIAL HETEROCYCLIC AMIDES | CRESTONE INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230203025-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | Sanford Burnham Prebys Medical Discovery Institute | 2023-06-29 | — | — | US | disclosed |
| US-20230203025-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | Sanford Burnham Prebys Medical Discovery Institute | 2023-06-29 | — | — | US | disclosed |
| US-11655225-B2 | Antimycobacterial heterocyclic amides | CRESTONE, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2021243230-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-12-02 | — | — | WO | disclosed |
| CN-112423746-A | Novel anti-mycobacterial heterocyclic amides | 克莱斯通公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | CRESTONE, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655225-B2 | Antimycobacterial heterocyclic amides | AADAC, CPS1, NAT1 | RAB9A 1973/4885NPC1 1093/4885CHKA 799/4885 |
| US-20210002239-A1 | Novel Antimycobacterial Heterocyclic Amides | AADAC, CPS1, ACAT1 | RAB9A 1886/4885NPC1 1474/4885CHKA 733/4885 |
| US-20230203025-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | GPR119, GUCY1A2, PRKG1 | RAB9A 1329/4885NPC1 224/4885CHKA 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.